Filter by
eXIthera Pharmaceuticals Announces FDA Acceptance of IND Application for Phase 2 Trial of EP-7041 for Thrombosis Prevention in COVID-19 Patients
Westborough, Mass., March 3, 2021 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the targeted inhibition of coagulation Factor XIa, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial […]
eXIthera Announces Publication of EP-7041 Data Demonstrating Safe Antithrombotic Activity in ECMO
Clinical and preclinical data published in Critical Care Explorations demonstrate that EP-7041 has the ability to inhibit ECMO-related thrombosis while minimizing the risk of unwanted bleeding Westborough, Mass., Sept. 17, 2020 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the inhibition of coagulation […]
eXIthera Appoints Michael Kurz, Ph.D., to Leadership Team
Dr. Kurz joins eXIthera as the Vice President of Translational Medicine and Medical Affairs Westborough, Mass., June 25, 2019 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications through the inhibition of Factor XIa, today announced the appointment of Michael Kurz, Ph.D., to the company’s leadership team. Dr. Kurz will join […]
eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
Antithrombotic EP-7041 safe and well tolerated; performed in antithrombotic test range associated with clinical efficacy and with fast onset/offset of activity.